API | zirconium silicate

zirconium silicate (Lokelma) Report issue

Small molecule Approved ^FDA

AACT ChEMBL Drugs@FDA MeSH PubChem

Active Ingredient History

NOW

Sodium zirconium cyclosilicate, sold under the brand name Lokelma, is a medication used to treat high blood potassium. Onset of effects occurs in one to six hours. It is taken by mouth. ^Wikipedia

Chemistry

SMILES: [Na+].[Na+].[Zr].[O-][Si]1([O-])O[Si]([O-])([O-])O[Si]([O-])([O-])O1
InChIKey: ARVUQMBOTBOHPL-UHFFFAOYSA-N
Mol. Mass: 365.455
ALogP: Missing data
ChEMBL Molecule:
sodium zirconium cyclosilicate

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: Missing data
Black Box: No
Availability: Prescription Only
Delivery Methods: Oral
Pro Drug: No

Drug Pricing (per unit)

United States

$12.3682 - $22.7613

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Organizations (18)

Research & Development (18)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (1)

Hyperkalemia (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (11)

Acidosis (Phase 3)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Drugs, Investigational (Phase 4)

Heart Failure (Phase 2)

Heart Failure, Systolic (Phase 4)

Hyperkalemia (Phase 4)

Hyperparathyroidism, Secondary (Phase 3)

Kidney Diseases (Phase 2)

Renal Insufficiency, Chronic (Phase 4)

Zirconium (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 30
# of Trial Organizations: 18

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue